BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

605 related articles for article (PubMed ID: 30555485)

  • 1. Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth
    Zhou XM; Li WQ; Wu YH; Han L; Cao XG; Yang XM; Wang HF; Zhao WS; Zhai WJ; Qi YM; Gao YF
    Front Immunol; 2018; 9():2821. PubMed ID: 30555485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR.
    Zhou X; Du J; Wang H; Chen C; Jiao L; Cheng X; Zhou X; Chen S; Gou S; Zhao W; Zhai W; Chen J; Gao Y
    Cell Commun Signal; 2020 Sep; 18(1):142. PubMed ID: 32894141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T-cell immunoglobulin and ITIM domain (TIGIT) receptor/poliovirus receptor (PVR) ligand engagement suppresses interferon-γ production of natural killer cells via β-arrestin 2-mediated negative signaling.
    Li M; Xia P; Du Y; Liu S; Huang G; Chen J; Zhang H; Hou N; Cheng X; Zhou L; Li P; Yang X; Fan Z
    J Biol Chem; 2014 Jun; 289(25):17647-57. PubMed ID: 24817116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemin blocks TIGIT/PVR interaction and induces ferroptosis to elicit synergistic effects of cancer immunotherapy.
    Zhou X; Li Y; Zhang X; Li B; Jin S; Wu M; Zhou X; Dong Q; Du J; Zhai W; Wu Y; Qiu L; Li G; Qi Y; Zhao W; Gao Y
    Sci China Life Sci; 2024 May; 67(5):996-1009. PubMed ID: 38324132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD155T/TIGIT Signaling Regulates CD8
    He W; Zhang H; Han F; Chen X; Lin R; Wang W; Qiu H; Zhuang Z; Liao Q; Zhang W; Cai Q; Cui Y; Jiang W; Wang H; Ke Z
    Cancer Res; 2017 Nov; 77(22):6375-6388. PubMed ID: 28883004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade.
    Hansen K; Kumar S; Logronio K; Whelan S; Qurashi S; Cheng HY; Drake A; Tang M; Wall P; Bernados D; Leung L; Ophir E; Alteber Z; Cojocaru G; Galperin M; Frenkel M; White M; Hunter J; Liang SC; Kotturi MF
    Cancer Immunol Immunother; 2021 Dec; 70(12):3525-3540. PubMed ID: 33903974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
    Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
    Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8
    Whelan S; Ophir E; Kotturi MF; Levy O; Ganguly S; Leung L; Vaknin I; Kumar S; Dassa L; Hansen K; Bernados D; Murter B; Soni A; Taube JM; Fader AN; Wang TL; Shih IM; White M; Pardoll DM; Liang SC
    Cancer Immunol Res; 2019 Feb; 7(2):257-268. PubMed ID: 30659054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma.
    Wu L; Mao L; Liu JF; Chen L; Yu GT; Yang LL; Wu H; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
    Cancer Immunol Res; 2019 Oct; 7(10):1700-1713. PubMed ID: 31387897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.
    Chauvin JM; Pagliano O; Fourcade J; Sun Z; Wang H; Sander C; Kirkwood JM; Chen TH; Maurer M; Korman AJ; Zarour HM
    J Clin Invest; 2015 May; 125(5):2046-58. PubMed ID: 25866972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity.
    Zhang Q; Bi J; Zheng X; Chen Y; Wang H; Wu W; Wang Z; Wu Q; Peng H; Wei H; Sun R; Tian Z
    Nat Immunol; 2018 Jul; 19(7):723-732. PubMed ID: 29915296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer.
    Fathi M; Pustokhina I; Kuznetsov SV; Khayrullin M; Hojjat-Farsangi M; Karpisheh V; Jalili A; Jadidi-Niaragh F
    IUBMB Life; 2021 May; 73(5):726-738. PubMed ID: 33686787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repositioning Azelnidipine as a Dual Inhibitor Targeting CD47/SIRPα and TIGIT/PVR Pathways for Cancer Immuno-Therapy.
    Zhou X; Jiao L; Qian Y; Dong Q; Sun Y; Zheng WV; Zhao W; Zhai W; Qiu L; Wu Y; Wang H; Gao Y; Chen J
    Biomolecules; 2021 May; 11(5):. PubMed ID: 34068552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD155/TIGIT, a novel immune checkpoint in human cancers (Review).
    Liu L; You X; Han S; Sun Y; Zhang J; Zhang Y
    Oncol Rep; 2021 Mar; 45(3):835-845. PubMed ID: 33469677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma.
    Chauvin JM; Ka M; Pagliano O; Menna C; Ding Q; DeBlasio R; Sanders C; Hou J; Li XY; Ferrone S; Davar D; Kirkwood JM; Johnston RJ; Korman AJ; Smyth MJ; Zarour HM
    Clin Cancer Res; 2020 Oct; 26(20):5520-5533. PubMed ID: 32591463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TX99 Is a Neutralizing Monoclonal Antibody Against Mouse TIGIT.
    Nakamura Y; Naito K; Yamashita-Kanemaru Y; Komori D; Hirochika R; Shibuya A; Shibuya K
    Monoclon Antib Immunodiagn Immunother; 2018 Apr; 37(2):105-109. PubMed ID: 29648914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR.
    Stanietsky N; Rovis TL; Glasner A; Seidel E; Tsukerman P; Yamin R; Enk J; Jonjic S; Mandelboim O
    Eur J Immunol; 2013 Aug; 43(8):2138-50. PubMed ID: 23677581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TIGIT safeguards liver regeneration through regulating natural killer cell-hepatocyte crosstalk.
    Bi J; Zheng X; Chen Y; Wei H; Sun R; Tian Z
    Hepatology; 2014 Oct; 60(4):1389-98. PubMed ID: 24912841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased Coexpression of PD-1, TIGIT, and KLRG-1 on Tumor-Reactive CD8
    Hutten TJA; Norde WJ; Woestenenk R; Wang RC; Maas F; Kester M; Falkenburg JHF; Berglund S; Luznik L; Jansen JH; Schaap N; Dolstra H; Hobo W
    Biol Blood Marrow Transplant; 2018 Apr; 24(4):666-677. PubMed ID: 29197680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T-cell Ig and ITIM domain regulates natural killer cell activation in murine acute viral hepatitis.
    Bi J; Zhang Q; Liang D; Xiong L; Wei H; Sun R; Tian Z
    Hepatology; 2014 May; 59(5):1715-25. PubMed ID: 24319005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.